Amplifon S.p.A.

LSE:0N61 Stock Report

Market Cap: €5.6b

Amplifon Valuation

Is 0N61 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0N61 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0N61 (€24.82) is trading below our estimate of fair value (€32.75)

Significantly Below Fair Value: 0N61 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0N61?

Key metric: As 0N61 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0N61. This is calculated by dividing 0N61's market cap by their current earnings.
What is 0N61's PE Ratio?
PE Ratio35.9x
Earnings€155.88m
Market Cap€5.59b

Price to Earnings Ratio vs Peers

How does 0N61's PE Ratio compare to its peers?

The above table shows the PE ratio for 0N61 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average32.1x
MDC Mediclinic International
21.9x10.7%UK£3.7b
CTEC ConvaTec Group
38.8x20.2%UK£4.7b
SN. Smith & Nephew
35.6x22.7%UK£8.6b
SPI Spire Healthcare Group
32.3x26.9%UK£914.6m
0N61 Amplifon
35.9x16.8%€5.6b

Price-To-Earnings vs Peers: 0N61 is expensive based on its Price-To-Earnings Ratio (35.9x) compared to the peer average (35.6x).

Price to Earnings Ratio vs Industry

How does 0N61's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0N61 35.9xIndustry Avg. 18.5xNo. of Companies9PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0N61 is expensive based on its Price-To-Earnings Ratio (35.9x) compared to the European Healthcare industry average (18.4x).

Price to Earnings Ratio vs Fair Ratio

What is 0N61's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0N61 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio35.9x
Fair PE Ratio35.4x

Price-To-Earnings vs Fair Ratio: 0N61 is expensive based on its Price-To-Earnings Ratio (35.9x) compared to the estimated Fair Price-To-Earnings Ratio (35.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0N61 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€24.82
€31.29
+26.1%
11.7%€38.00€23.50n/a16
Dec ’25€24.02
€32.22
+34.1%
9.5%€38.00€27.40n/a14
Nov ’25€25.68
€32.77
+27.6%
9.1%€38.00€27.40n/a14
Oct ’25€25.67
€33.86
+31.9%
8.5%€38.00€29.10n/a14
Sep ’25€29.28
€33.94
+15.9%
8.4%€38.00€29.10n/a14
Aug ’25€28.45
€34.41
+20.9%
7.9%€38.00€30.00n/a14
Jul ’25€33.29
€35.91
+7.9%
8.9%€42.00€30.90n/a14
Jun ’25€33.88
€35.91
+6.0%
8.9%€42.00€30.90n/a14
May ’25€31.43
€34.90
+11.0%
7.3%€40.00€29.80n/a14
Apr ’25€33.79
€34.71
+2.7%
9.5%€40.10€29.00n/a15
Mar ’25€31.39
€32.36
+3.1%
10.6%€38.00€24.00n/a15
Feb ’25€29.92
€32.36
+8.2%
10.6%€38.00€24.00n/a15
Jan ’25€31.26
€31.37
+0.4%
11.0%€37.00€24.00n/a15
Dec ’24€28.21
€31.17
+10.5%
10.2%€37.00€24.00€24.0215
Nov ’24€26.44
€31.40
+18.8%
10.1%€37.00€24.00€25.6815
Oct ’24€28.17
€33.86
+20.2%
7.7%€40.40€29.20€25.6714
Sep ’24€29.48
€33.72
+14.4%
8.4%€40.40€29.20€29.2814
Aug ’24€30.25
€33.72
+11.5%
8.4%€40.40€29.20€28.4514
Jul ’24€33.66
€34.03
+1.1%
11.2%€41.50€28.50€33.2914
Jun ’24€32.37
€33.46
+3.4%
14.5%€41.50€22.00€33.8814
May ’24€33.30
€30.02
-9.9%
12.3%€39.00€22.00€31.4313
Apr ’24€31.94
€28.96
-9.3%
9.4%€33.00€22.00€33.7914
Mar ’24€27.21
€28.35
+4.2%
9.2%€32.00€22.00€31.3914
Feb ’24€25.63
€28.73
+12.1%
9.8%€34.00€22.00€29.9214
Jan ’24€27.81
€30.43
+9.4%
8.9%€35.00€26.20€31.2613
Dec ’23€27.51
€30.59
+11.2%
9.0%€35.00€26.20€28.2112

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 13:49
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Amplifon S.p.A. is covered by 31 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Paola SagliettiBanca Akros S.p.A. (ESN)
Hassan Al-WakeelBarclays
Hugo SolvetBNP Paribas Exane